Strategic Partnerships Renalytix has active partnerships and clinical integrations with US health systems and digital health platforms, signaling a network-ready opportunity to cross-sell kidneyintelX.dkd with care management solutions and expand enterprise-wide adoption.

Expansion Momentum Recent US clinical collaborations and plans to scale through new physician practices indicate growing demand and a larger addressable market, suggesting a sales focus on hospital systems, accountable care organizations, and major health networks.

Financial Signals Revenue progression shows growth potential but with longer conversion cycles for healthcare integrations; sales teams should emphasize value realization, cost savings, and rapid ROI to overcome pipeline conversion hurdles.

Clinical Evidence Two-year study data linking the test to improved patient health strengthens the case for payer discussions and hospital value-based purchasing, enabling targeted proposals around reimbursement and health outcome guarantees.

Integrated Care The combined use of FDA-approved kidneyintelX.dkd with Carna Health’s AI platform presents a compelling bundled offering for risk-guided, precision intervention, ideal for multi-stakeholder procurement conversations across nephrology, endocrinology, and primary care.